Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries.
Cold allodynia is a frequent clinical symptom of patients with neuropathic pain. Despite numerous studies of cold allodynia, using animal models of neuropathic pain, little is known about its underlying mechanisms. This study was performed to establish a method for the pharmacologic evaluation of cold allodynia using several analgesics in a chronic constriction injury (CCI) rat model of neuropathic pain. Compared with the results obtained before the CCI operation, the CCI rats placed on a cork plate at 20 degrees C exhibited a slight change in the paw withdrawal latency because of the mechanical stimulus mediated by the injured paw touching the plate. By contrast, there was a significant reduction in the paw withdrawal latency on a cold metal plate compared with that on the cork plate after the CCI surgery, with the maximum decrease occurring on postoperative day 7. This reduction is thought to specifically reflect cold-induced pain behavior. In addition, both naïve and CCI rats showed behavioral changes at 5 and 0 degrees C, but not at 10 degrees C or higher. Interestingly, a subcutaneous morphine dose of 6 mg/kg completely inhibited cold allodynia induced at 10 degrees C on postoperative day 7. Under this condition, both the sodium channel blocker mexiletine (10 and 30 mg/kg, subcutaneously) and the calcium channel alpha2delta subunit blocker pregabalin (30 and 100 mg/kg, orally) significantly suppressed cold allodynia. Additionally, both resiniferatoxin (0.3 mg/kg, subcutaneously), an ultrapotent analog of capsaicin that desensitizes C fibers, and the VR1 channel antagonist N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1(2H)-carboxamide (10 and 30 mg/kg, orally) significantly prolonged the paw withdrawal latency. In conclusion, our data suggest that the activation of C fibers mediates cold allodynia.
Tanimoto-Mori
Sachi
S
Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc., Aichi, Japan. Sachi.Tanimoto@pfizer.com
Nakazato-Imasato
Etsuko
E
Toide
Katsuo
K
Kita
Yasuhiro
Y
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002908:Chronic Disease; D003080:Cold Temperature; D003251:Constriction, Pathologic / Q000503:physiopathology; D004195:Disease Models, Animal; D004224:Diterpenes / Q000494:pharmacology; D008297:Male; D008801:Mexiletine / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D036421:Nerve Fibers, Unmyelinated / Q000187:drug effects / Q000502:physiology; D010146:Pain / Q000503:physiopathology*; D010147:Pain Measurement / Q000379:methods*; D010523:Peripheral Nervous System Diseases / Q000503:physiopathology*; D000069583:Pregabalin; D011719:Pyrazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D012584:Sciatic Nerve / Q000503:physiopathology; D026941:Sodium Channel Blockers / Q000494:pharmacology; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000494:pharmacology
D000701:Analgesics, Opioid; D002121:Calcium Channel Blockers; D004224:Diterpenes; C475772:N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide; D011719:Pyrazines; D011725:Pyridines; D026941:Sodium Channel Blockers; D050916:TRPV Cation Channels; C493922:Trpv1 protein, rat; D008801:Mexiletine; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D009020:Morphine; C024353:resiniferatoxin